What medications and dosing regimens are recommended for treating neuropathic pain?

Neuropathy Pain Medications

Start with either a tricyclic antidepressant (nortriptyline or desipramine 25-150 mg/day), an SNRI (duloxetine 60 mg/day or venlafaxine 150-225 mg/day), or gabapentin (titrated to 1800-3600 mg/day divided three times daily) as first-line therapy. 1, 2

First-Line Medications

The most recent high-quality meta-analysis from 2025 establishes clear efficacy rankings 2:

• Tricyclic Antidepressants (TCAs): NNT 4.6 - most effective option

  • Use secondary amines (nortriptyline or desipramine) to minimize anticholinergic effects
  • Start 10-25 mg at bedtime, titrate slowly to 75-150 mg/day
  • Obtain ECG if patient >40 years old; avoid if cardiac conduction abnormalities present
  • Allow 6-8 weeks for adequate trial (including 2 weeks at maximum tolerated dose)
  • Caution: keep doses <100 mg/day when possible due to cardiac toxicity risk 1

• Gabapentin: NNT 8.9 (as part of α2δ-ligands class)

  • Specific dosing protocol: 300 mg day 1,600 mg day 2,900 mg day 3 3
  • Target dose 1800 mg/day (divided three times daily) for efficacy
  • May increase to 3600 mg/day if needed and tolerated
  • Adverse effects typically mild-moderate, subsiding within 10 days 3

• SNRIs: NNT 7.4

  • Duloxetine 60 mg once daily (proven in diabetic peripheral neuropathy specifically)
  • Venlafaxine 150-225 mg/day
  • Simpler dosing than TCAs, better tolerated than TCAs 1

Note on pregabalin: While international guidelines recommend it first-line, more recent French guidelines downgraded it to second-line due to lower efficacy in recent studies and misuse potential 4. Given this controversy and gabapentin's established efficacy, gabapentin is preferred over pregabalin.

Localized Peripheral Neuropathic Pain

For focal peripheral neuropathic pain, add topical agents as first-line:

• Lidocaine 5% patches: NNT 14.5 - apply to affected area 2
• Can be used alone or combined with systemic first-line therapy 1

Second-Line Options (If First-Line Inadequate)

If partial relief after adequate first-line trial (pain remains ≥4/10), add a different first-line medication from another class 1. If <30% pain reduction, switch to alternative first-line agent.

Additional second-line options:

• Tramadol: 200-400 mg/day divided
• Combination therapy: Antidepressant + gabapentinoid 5
• Capsaicin 8% patches: NNT 13.2 (for focal peripheral neuropathic pain only) 2
• Botulinum toxin A: NNT 2.7 (for focal peripheral neuropathic pain) 2

Third-Line Options (Refractory Cases)

When first and second-line treatments fail:

• Strong opioids: NNT 5.9, but NNH 15.4 - use only when no alternatives available 2
• Repetitive transcranial magnetic stimulation (rTMS): High-frequency targeting motor cortex, NNT 4.2 2
• Spinal cord stimulation: For failed back surgery syndrome and painful diabetic polyneuropathy 5
• Refer to pain specialist or multidisciplinary pain center 1

Critical Pitfalls to Avoid

• Don't use capsaicin cream (low concentration) - very low certainty evidence, NNT only 6.1 2
• Cannabis-based medicines have no clear evidence for neuropathic pain relief - very low to low certainty evidence across all formulations 6
• Don't underdose gabapentin - 900 mg/day is starting point, not target; must reach 1800 mg/day minimum for efficacy 3
• Don't rush TCA trials - requires full 6-8 weeks including 2 weeks at maximum dose 1
• Screen cardiac risk before TCAs - obtain ECG in patients >40 years, avoid in ischemic heart disease or conduction abnormalities 1

Treatment Algorithm Summary

1. Assess and diagnose neuropathic pain; treat underlying cause if possible
2. Initiate first-line: TCA (nortriptyline/desipramine) OR SNRI (duloxetine/venlafaxine) OR gabapentin
3. Add topical lidocaine if localized peripheral neuropathic pain
4. Reassess at 6-8 weeks: If pain ≥4/10, add second first-line agent from different class
5. If inadequate response: Progress to second-line options (tramadol, combinations, capsaicin 8%, BTX-A)
6. If still refractory: Consider third-line (opioids as last resort, neuromodulation) or refer to specialist

The evidence strongly supports TCAs as most effective (lowest NNT), but SNRIs and gabapentin offer better tolerability profiles with reasonable efficacy 2.